Law firm WeissLaw said it is investigating “possible breaches of fiduciary duty and other violations of law” by the board of directors of Big Rock Partners Acquisition in connection with the company’s proposed $500 million merger with privately-held clinical stage, small molecule pharmaceutical company NeuroRx. Read more.
WeissLaw Says it’s Investigating Big Rock Partners/NeuroRx Deal
